Swiss company Basilea Pharmaceutica has entered an agreement to provide US-based Pfizer with exclusive commercialisation rights to Cresemba (isavuconazole) in Europe for the treatment of invasive fungal diseases (IFDs).
Cresemba is an anti-fungal treatment for adults with diagnosed invasive aspergillosis and mucormycosis, two serious infections associated with high morbidity and mortality among immunocompromised patients, such as those with advanced HIV infection or cancer.
It is an intravenous (IV) and oral azole antifungal and the active agent of the prodrug isavuconazonium sulfate.
Under the deal, Pfizer will have exclusive rights to distribute and market Cresemba in Europe, including Austria, France, Germany, Italy and the UK, where the treatment is currently available.
However, commercialisation rights do not include the Nordic countries, Denmark, Finland, Norway, Sweden and Iceland.
The company will also be responsible for additional Cresemba launches, mainly across Europe, expected throughout this year and next year.
Pfizer Europe, Africa / Middle East biosimilars global president Richard Blackburn said: “The addition of Cresemba to Pfizer’s broad anti-fungal portfolio reaffirms our commitment to provide innovative treatments to patients who are increasingly susceptible to life-threatening fungal infections.
“We believe our well-established global presence, together with our deep knowledge of infectious diseases, will enable us to meaningfully address a major unmet medical need.”
Basilea Pharmaceutica will continue its role as the marketing authorisation holder for the European Union (EU).
Basilea Pharmaceutica is an international biopharmaceutical company that specialises in the research and development of anti-infective and oncological medicines.